At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
brentuximab vedotin +1 moredrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin and nivolumab for Hodgkin Lymphoma. Completed, enrolled 93 participants across 13 sites.
Detailed Summary
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionMar 2018
Study CompletionOct 2021
TodayJul 2026
First PostedOct 8, 2015
Enrollment StartOct 31, 2015
Primary CompletionMar 1, 2018
Study CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.7 years ago
Interventions
brentuximab vedotindrug
1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
nivolumabdrug
3 mg/kg by intravenous (IV) infusion for up to 4 cycles